This company may still be operating, however this listing is no longer active. Find out why through their latest events.

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Annexin Pharmaceuticals Crescita futura

Annexin Pharmaceuticals is forecast to grow earnings and revenue by 46.9% and 178.1% per annum respectively.

46.9%

Tasso di crescita degli utili

n/a

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	65.1%
Tasso di crescita dei ricavi	178.1%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	15 Apr 2024

Nessun aggiornamento

Previsioni di crescita degli utili e dei ricavi

OM:ANNX BTA - Stime future degli analisti e dati finanziari passati (SEK Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2025	40	-17	N/A	N/A	1
12/31/2024	N/A	-52	N/A	N/A	1
3/31/2024	N/A	-46	-45	-45	N/A
12/31/2023	N/A	-44	-43	-43	N/A
9/30/2023	N/A	-40	-43	-43	N/A
6/30/2023	N/A	-38	-40	-40	N/A
3/31/2023	N/A	-41	-43	-43	N/A
12/31/2022	N/A	-41	-41	-41	N/A
9/30/2022	N/A	-47	-39	-39	N/A
6/30/2022	N/A	-45	-39	-39	N/A
3/31/2022	N/A	-43	-40	-40	N/A
12/31/2021	N/A	-52	-45	-45	N/A
9/30/2021	N/A	-53	-47	-47	N/A
6/30/2021	N/A	-53	-48	-48	N/A
3/31/2021	N/A	-55	-48	-48	N/A
12/31/2020	N/A	-44	-39	-39	N/A
9/30/2020	N/A	-38	-34	-34	N/A
6/30/2020	N/A	-36	-30	-30	N/A
3/31/2020	N/A	-31	-24	-24	N/A
12/31/2019	N/A	-28	-26	-26	N/A
9/30/2019	N/A	-25	-24	-24	N/A
6/30/2019	N/A	-24	-26	-26	N/A
3/31/2019	N/A	-25	-27	-27	N/A
12/31/2018	N/A	-29	-29	-29	N/A
9/30/2018	N/A	-31	-33	-33	N/A
6/30/2018	N/A	-30	-36	-35	N/A
3/31/2018	N/A	-32	-39	-39	N/A
12/31/2017	N/A	-31	N/A	-39	N/A
9/30/2017	N/A	-25	N/A	-36	N/A
6/30/2017	N/A	-26	N/A	-29	N/A
3/31/2017	N/A	-17	N/A	-18	N/A
12/31/2016	N/A	-10	N/A	-10	N/A
12/31/2015	N/A	-5	N/A	-5	N/A

Guadagni vs tasso di risparmio: ANNX BTA is forecast to remain unprofitable over the next 3 years.

Guadagni vs Mercato: ANNX BTA is forecast to remain unprofitable over the next 3 years.

Guadagni ad alta crescita: ANNX BTA is forecast to remain unprofitable over the next 3 years.

Ricavi vs Mercato: ANNX BTA's revenue (178.1% per year) is forecast to grow faster than the Swedish market (1.8% per year).

Ricavi ad alta crescita: ANNX BTA's revenue (178.1% per year) is forecast to grow faster than 20% per year.

ROE futuro: Insufficient data to determine if ANNX BTA's Return on Equity is forecast to be high in 3 years time